Market revenue in 2023 | USD 2,785.0 million |
Market revenue in 2030 | USD 4,748.0 million |
Growth rate | 7.9% (CAGR from 2023 to 2030) |
Largest segment | Active pharmaceutical ingredients (api) |
Fastest growing segment | Active Pharmaceutical Ingredients (API) |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Active Pharmaceutical Ingredients (API), Finished Drug Products |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Thermo Fisher Scientific Inc, Siegfried Holding AG, Eurofins Scientific SE, Aurigene Pharmaceutical Services |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to small molecule cdmo market will help companies and investors design strategic landscapes.
Active pharmaceutical ingredients (api) was the largest segment with a revenue share of 62.28% in 2024. Horizon Databook has segmented the Germany small molecule cdmo market based on active pharmaceutical ingredients (api), finished drug products covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany small molecule cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Germany small molecule cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account